Do You Believe in GeneDx Holdings Corp.’s (WGS) Durable Competitive Moat? Soumya Eswaran May 4, 2026 3 min read WGS Fred Alger Management, an investment management company, released its "Alger Small Cap Focus Fund" first-quarter 2026 investor letter. A copy of the letter can be downloaded here.
In the first quarter of 2026, the Class A shares of the Alger Small Cap Fund underperformed the Russell 2000 Growth Index. The Information Technology and Consumer Discretionary sectors contributed to the performance, while Health Care and Energy detracted from the performance. US equities experienced a volatile period in the first quarter of 2026, driven by AI disruption and the U.S.-Iran conflict that began in late February.
The Fund identifies opportunities in companies that are adopting and facilitating the technology as it evolves into an agentic phase while navigating AI disruption challenges. In addition, please check the Fund's top five holdings to know its best picks in 2026. In its first-quarter 2026 investor letter, Alger Small Cap Focus Fund highlighted stocks like GeneDx Holdings Corp. (NASDAQ:WGS).
GeneDx Holdings Corp. (NASDAQ:WGS) is a genomics company that offers pediatric and rare disease diagnostics services. On May 1, 2026, GeneDx Holdings Corp. (NASDAQ:WGS) closed at $65.38 per share. One-month return of GeneDx Holdings Corp. (NASDAQ:WGS) was -1.85%, and its shares gained 2.46% over the past 52 weeks.
GeneDx Holdings Corp. (NASDAQ:WGS) has a market capitalization of $1.92 billion. Alger Small Cap Focus Fund stated the following regarding GeneDx Holdings Corp. (NASDAQ:WGS) in its Q1 2026 investor letter: "GeneDx Holdings Corp. (NASDAQ:WGS) is a specialty genomics laboratory focused on delivering complex genetic tests, including whole exome and genome sequencing, to diagnose pediatric rare diseases. The company possesses a comprehensive and proprietary database of genetic data that enables it to deliver superior diagnostic yields relative to competitors and alternative testing modalities, creating a meaningful competitive advantage in a highly specialized market.
During the quarter, shares detracted from performance driven by two primary factors. First, while the company reported fiscal fourth quarter revenue above analyst estimates, the magnitude of the upside was lower than investors anticipated as average selling prices per test remained steady on a sequential basis. Second, the launch of a competing genomics assay by a well-known diagnostics peer introduced concerns around potential market share erosion in the rare disease testing space.
Extract — continue reading at the source.
